Please wait while the formulary information is being retrieved.
DEMSER (METYROSINE)
- Pheochromocytoma adjunct therapy
250 mg capsule
- 1 capsule (250 mg) by oral route 4 times per day
Pheochromocytoma adjunct therapy
- 4 capsules (1,000 mg) by oral route 4 times per day
- 1 capsule (250 mg) by oral route 4 times per day
- 2 capsules (500 mg) by oral route 4 times per day
- 3 capsules (750 mg) by oral route 4 times per day
- None
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- Crystalluria
- Extrapyramidal disease
- Hypotension
- Hypovolemia
- Parkinsonism
Severe
Moderate
- Depression
- Disease of liver
- Kidney disease with reduction in GFR
- Urolithiasis
DEMSER (METYROSINE)
- Pheochromocytoma adjunct therapy
- Extrapyramidal disease
- Severe diarrhea
- Drowsy
More Frequent
Severe
Less Severe
- None
- Abdominal pain with cramps
- Disorder of ejaculation
- Erectile dysfunction
- Galactorrhea not associated with childbirth
- Gynecomastia
- Nasal congestion
- Nausea
- Vomiting
- Xerostomia
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute confusion
- Allergic dermatitis
- Anaphylaxis
- Anemia
- Angioedema
- Crystalluria
- Depression
- Dyspnea
- Dysuria
- Eosinophilia
- Hallucinations
- Hematuria
- Parkinsonism
- Pharyngeal edema
- Skin rash
- Swelling of ankles or feet
- Thrombocytopenic disorder
- Thrombocytosis
- Trismus
- Urolithiasis
- Urticaria
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
None
Metyrosine
- Severity Level:
C
- Additional Notes:
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Metyrosine
Insuff data avail. molecular wt low enough for possible breastmilk excretion
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insuff data avail. molecular wt low enough for possible breastmilk excretion |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Pheochromocytoma adjunct therapy | |
| C74.1 | Malignant neoplasm of medulla of adrenal gland |
| C74.10 | Malignant neoplasm of medulla of unspecified adrenal gland |
| C74.11 | Malignant neoplasm of medulla of right adrenal gland |
| C74.12 | Malignant neoplasm of medulla of left adrenal gland |
| D35.0 | Benign neoplasm of adrenal gland |
| D35.00 | Benign neoplasm of unspecified adrenal gland |
| D35.01 | Benign neoplasm of right adrenal gland |
| D35.02 | Benign neoplasm of left adrenal gland |
| E31.22 | Multiple endocrine neoplasia [MEn] type IIA |
| E31.23 | Multiple endocrine neoplasia [MEn] type IIB |
| 0-9 | A-Z |
|---|---|
| C74.1 | Malignant neoplasm of medulla of adrenal gland |
| C74.10 | Malignant neoplasm of medulla of unspecified adrenal gland |
| C74.11 | Malignant neoplasm of medulla of right adrenal gland |
| C74.12 | Malignant neoplasm of medulla of left adrenal gland |
| D35.0 | Benign neoplasm of adrenal gland |
| D35.00 | Benign neoplasm of unspecified adrenal gland |
| D35.01 | Benign neoplasm of right adrenal gland |
| D35.02 | Benign neoplasm of left adrenal gland |
| E31.22 | Multiple endocrine neoplasia [MEn] type IIA |
| E31.23 | Multiple endocrine neoplasia [MEn] type IIB |
Formulary Reference Tool